Grogu said:
kazza94x said:
spanky2026 said:
Still purchasing compounded, and obsessively tracking each sign that one more compounder is exiting the GLP market. (The BPI and ProRX mess still has me rattled)
Which drama are you referring to?
Drama seems to follow the compounded glp1 world constantly.
Maybe the most notable example came in March 2025, when it looked like compounded tirzepatide might be shut down for good. Lilly had just won a court ruling that was expected to halt large-scale production of compounded tirzepatide, though specialized individual dosing and additives were still going to be permitted. That prospect drove people to buy up and stash supplies ahead of March 2025. Nearly every major 503b outsourcing facility — BPI, ProRx, Olympia, Empower, and others — announced they would halt output. These 503b facilities fall under FDA oversight, and when a drug is in shortage they are permitted to mass produce compounded forms of it.
More drama tends to follow because 503b outsourcing facilities get FDA inspections. So when an inspection report turns up with unfavorable findings, the reaction can be huge. A lot of people suspected ProRx was just "water".